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INTRODUCTION
The ginseng root has been used empirically for thousands
of years in Asian countries. Since 1965, several pharmaco-
logical activities of ginseng extracts or ginseng dammarane
saponin have been reported, including effects on the central
nervous system, antipsychotic action, tranquillizing effects,
protection from stress ulcers, increase of gastrointestinal motil-
ity, antifatigue action, endocrinological effects, enhancement
of sexual behavior, acceleration of metabolism, syntheses of
carbohydarates, lipids, RNA, and proteins (1-4).
The ginseng plant is deciduous perennial belonging to the
Araliaceae family. Of the 13 species (5, 6), the most promi-
nent are Panax ginseng C.A. Meyer, which is cultivated in
Korea, Japan, China, Russia, the United States of America,
and Germany, P. quinquefolius L. (American ginseng) found
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Epidemiological Study on Cancer Prevention by Ginseng:
Are All Kinds of Cancers Preventable by Ginseng?
In the light of experimental results, two case-control studies and one cohort study
in a population of ginseng cultivation area were conducted to confirm whether
ginseng has any anticarcinogenic effect on human cancers. All participants were
interviewed using a standardised questionnaire to obtain the information on demo-
graphics, cigarette smoking, alcohol consumption and ginseng intake. In 905
pairs case-control study, 62% had a history of ginseng intake compared to 75%
of the controls, a statistically significant difference (p<0.01). The odds ratio (OR)
for cancer in relation to ginseng intake was 0.56. In extended case-control study
with 1987 pairs, the ORs for cancer were 0.37 in fresh ginseng extract users,
0.57 in white ginseng extract users, 0.30 in white ginseng extract users, 0.30 in
white ginseng powder users, and 0.20 in red ginseng users. Those who took
fresh ginseng slices, fresh ginseng juice, and white ginseng tea, however, did
not show decrease in the risk. Overall, the risk decreased as the frequency and
duration of ginseng intake increased. With respect to the site of cancer, the ORs
for cancers of the lip, oral cavity, pharynx, esophagus, stomach, colorectum,
liver, pancreas, larynx, lung and ovary were significantly reduced by ginseng
intake. Smokers with ginseng intake showed lower ORs for cancers of lung, lip,
oral cavity and pharynx and liver than those without ginseng intake. In 5 yr fol-
low-up cohort study conducted in the ginseng cultivation area, Kangwha-eup,
ginseng intakers had significantly lower risk than non-intakers. As for the type of
ginseng, cancer risk significantly decreased among intakers of fresh ginseng
extract, alone or together with other ginseng preparations. Among 24 red gin-
seng intakers, no cancer death occurred during the follow-up period. The risk for
stomach and lung cancers was significantly reduced by ginseng intake, showing
a statistically significant dose-response relationship in each follow-up year. In
conclusion, Panax ginseng C.A. Meyer has been established as non-organ spe-
cific cancer preventive, having dose response relationship. These results war-
rant that ginseng extracts and its synthetic derivatives should be examined for
their preventive effect on various types of human cancers.
Key Words : Panax ginseng C.A. Meyer; Case-Control Studies; Cohort Studies; Neoplasms; Preven-
tion and control; Anticarcinogenic Agents
And the earth brought forth grass, and herb yields seed according to its kind, and the tree that yields fruit,
whose seed is in itself according to its kind. And God saw that it was good. 
Genesis 1 :12 - Old TestamentS20 T.-K. Yun, S.-Y. Choi, H.Y. Yun
in southern Canada and the U.S.A., and P. japonicus C.A.
Meyer (Japanese ginseng) grown in Japan.
We have proposed that the life-prolonging effect of gin-
seng described by Shennong (7) during the Liang Dynasty
in China may be due to the preventive activity of ginseng
against the development of cancers. Employing a long term
anticarcinogenesis model using newborn mice (8, 9), we
carried out extensive experiments in 1978 to investigate
whether ginseng inhibited carcinogenesis, and demonstrat-
ed that the red ginseng extracts of Panax ginseng C.A. Meyer
cultivated in Korea had anticarcinogenic activity against
lung tumors and liver cancer induced by urethane or afla-
toxin B1.
The extract was found to partly elevate natural killer cell
activity (10), the results providing the hope for natural
products preventing human cancers. The medium-term (9
weeks) model system also revealed anticarcinogenicity of
ginseng on pulmonary adenoma induced by benzo(a)pyrene
(BP) in newborn mice (11-14).
Employing BP as carcinogen, we further investigated
whether fresh ginseng or white ginseng also had the similar
anticarcinogenic effects, and whether the anticarcinogenic
effects depended on types and ages of ginseng. We found a
significant anticarcinogenic effect of 6-yr-old dried powder
or fresh ginseng extract, 5- and 6-yr-old white ginseng pow-
der or extract, and 4-, 5-, and 6-yr-old red ginseng powder
or extract (15-17). The results demonstrated that the anti-
carcinogenicity was more prominent in aged or heat treated
extract of fresh ginseng and red ginseng prepared by steam-
ing.
In light of the above described evidences, in 1987 we began
a case-control study with 905 pairs (18) to confirm whether
red ginseng extracts had anticarcinogenic effect on human
cancers as much as on mice, and we later extended the num-
ber of subjects to 1,987 pairs (19) from 905 pairs.
Also, a prospective study (20) was started to find whether
ginseng intake was related to the type of cancers, and to
evaluate the preventive effect of ginseng among the popula-
tion residing in ginseng cultivation area 6 months after the
first case-control study (in August 1987) and compared the
results with three independent analyses in 10 yr of follow up
period.
MATERIALS AND METHODS
Case-control study with 905 pairs
The cases and controls were selected from the patients
admitted to the Korea Cancer Center Hospital (KCCH),
Seoul. As a major cancer centre in Korea, the KCCH diag-
nosed average 5,000 new cancer patients annually between
1 July 1982 and 30 June 1987. These represent an average
of 14% of all cancer patients diagnosed annually in 66 hos-
pitals in Korea (21). Selection criteria for cases were: newly
diagnosed cancer during the period of 1 February 1987
through 31 January 1988, diagnosis of cancer by pathologi-
cal examination, and 20 yr of age or older at diagnosis.
Patients admitted to the intensive care unit or the otolaryn-
gology department were excluded from the study, because
of the difficulty in answering questions. A total of 905 cases
met these criteria and all cases agreed to participate in the
study.
One control was selected for each case from a pool of patients
diagnosed with non-cancerous diseases at the same hospital
by matching gender, age at diagnosis (±2 yr), and date of
admission (±3 months). When more than one control fell
within the selection range, the control which had the admis-
sion date closest to that of the cancer patient was selected as
the matched control. Patients whose final diagnoses were
not cancer but whose diseases were associated with smoking
or alcohol consumption were also excluded from the control
group. Among the controls were those suffering from car-
diovascular disease, chronic obstructive pulmonary disease,
peptic ulcer, and liver cirrhosis.
Two trained interviewers visited the 905 case-control pairs
in the hospital. To prevent possible bias between the inter-
viewers, a standardized questionnaire was administered to
each case-control pair by the same interviewer. During the
interview, some information on demographic characteristics
(i.e., age, marital status, education, occupation and income),
life-style (i.e., cigarette smoking, alcohol consumption and
others), and ginseng consumption were obtained (18).
In order to collect information on ginseng intake, a dietary-
recall method commonly employed in epidemiological stud-
ies on diet and disease was used (22). In the questionnaire,
ginseng types were classified into fresh ginseng, white gin-
seng and red ginseng. Fresh ginseng is less than four yr old
and can be consumed in the fresh state. White ginseng is
grown for four to six year, peeled and dried to reduce the water
content to 12% or less. Red ginseng is harvested after six
year, steamed, and dried. In the questionaire, each type of
ginseng was further grouped into several forms of ginseng
product; i.e., fresh sliced, juice, extract, powder, tea, tablet,
capsule and other forms. The lifetime consumption of gin-
seng was assessed by asking types and products used, frequen-
cy of intake per day, week, and month for each decade of life.
In addition, multiple combinations among fresh, white and
red ginsengs were included.
Interviews on ginseng intake were carried out by asking
the following series of questions; 1) Have you ever consumed
ginseng? 2) At what age did you first take ginseng? 3) What
type of ginseng products have you taken? and 4) How often
(frequency) and how long (duration) have you used it? The
frequency of ginseng intake was divided into four categories:
no intake, 1-3 times per year, 4-11 times per year, and more
than once a month (12 times or more per year). The trained
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tionnaire that took approximately half an hour to complete.
To measure the reliability of recall of ginseng use, a second
interview was carried out with 180 randomly selected sub-
jects by the same interviewer one year after the first inter-
view, using the same questionnaire. The strength of agree-
ment on ginseng intake information obtained from the two
interviews was measured by Kappa statistic (23).
Case-control study with 1,987 pairs
In order to explore further (a) the types of ginseng pro-
ducts that have the most prominent cancer preventive effect,
(b) the reproducibility of the dose-response relationship, (c)
the duration of ginseng consumption that has a significant
preventive effect, (d) the types of cancer that can be prevent-
ed by ginseng, and (e) the effect of ginseng on cancers asso-
ciated with smoking, we increased the number of subjects
to 1987 pairs for a case-control study (20).
All the cases were admitted to the Korea Cancer Center
Hospital between February 1987 and December 1990, and
were confirmed by cytological and/or histopathological exam-
ination.
The cases and controls were selected as described in the
previous study (18). The disease sites of male control patients
were stomach (495), thyroid (120), colon (81), kidney (93),
oral cavity (85), lung (51), and others (95). For female con-
trol patients, they were uterus (351), breast (177), thyroid
(170), ovary (75), stomach (46), liver (25), colon (16), and
others (55). The types of diseases of the controls were main-
ly acute diseases; acute or unspecified gastritis, goiter, acute
appendicitis, colon obstruction, acute pyelonephritis, kidney
stone, tonsilitis, laryngopharyngitis, pneumonia and pleurisy.
All questionnaires were checked as described in the earlier
case-control study (18) of 905 pairs. To evaluate the accura-
cy of the answers to the questionnaire, 10% of each cases and
controls were evaluated by k value (24).
Prospective study with population
The study population was selected from persons who were
listed in the 1987 resident’ s list which was registered at the
provincial government offices of the ginseng production
areas. These lists contain the name, sex, date of birth, and
permanent and present addresses. Subjects born before 1947
(over 40 yr) were selected. A cohort of 4,634 persons over
40 yr of age residing in Kangwha-eup was interviewed and
examined between August 1987 and December 1989. Each
study subject was interviewed by means of a standard ques-
tionnaire about demographic characteristics, life-long occu-
pation, smoking and drinking habits, and past history of
diseases, etc. In an attempt to obtain detailed information
on ginseng intake, we used the same questionnaire as used
in the previous two case-control studies (18, 19). The inter-
viewers had been instructed and trained beforehand to ensure
uniformity in the method of inquiry. We carried out follow-
up studies on all cohort members to document development
of cancer and other illnesses and to update exposure informa-
tion. Length of follow-up was calculated for each individual
in the study as the number of days elapsed since completion
of the questionnaire until death from cancer or other diseases.
Deaths among the cohort from August 1987 to December
1997 were traced by population registration cards with no
follow-up loss. A cohort member was classified as a cancer
case if they had any disease code of cancer in hospital records,
death certificates of the provincial government, privileged
data of Korea Medical Insurance Corporation, etc.
RESULTS
905 pairs case-control study
Distribution of selected cases by cancer site for each gen-
der is shown in Table 1. Of the 905 cases, 562 (62%) had a
history of ginseng intake compared to 674 (75%) of the













Table 1. Distribution of  cancer sites in 905 case  subjects
Type of ginseng Cases Controls Odds ratio 95% CI*
No intake of ginseng 343 231 1.00 Reference
Intake of ginseng 562 (62%) 674 (75%) 0.56 0.46-0.69
Fresh ginseng
Slice 103 94 0.74 0.53-1.04
Juice 39 34 0.77 0.46-1.30
Extract 13 64 0.14 0.07-0.26
White ginseng
Powder 28 43 0.44 0.26-0.75
Extract 247 261 0.64 0.50-0.82
Tea 37 27 0.93 0.53-1.61
Red ginseng
Extract 2 3 0.45 0.05-3.32
Combination 10 25 0.27 0.13-0.53
Table 2. Odds ratios and 95% confidence intervals (CI) for
cancers by ginseng intake in 905 pairs
Adjusted for age, sex, marital status, educations, smoking, and alcohol
consumption. *CI: confidence intervalS22 T.-K. Yun, S.-Y. Choi, H.Y. Yun
to ginseng intake was 0.56 [95% confidence interval (CI),
0.45-0.69]. Ginseng extract and powder were shown to be
more effective than fresh sliced ginseng, the juice, or tea in
reducing the OR (Table 2). With the increased frequency of
ginseng intake, ORs decreased in both male and female
(Table 3). A trend test showed a significant decrease in the
number of cancer cases among those who reported an in-
creased frequency of ginseng intake for males (p<10-5) as well
as for females (p<0.05). The reliability of recall for ginseng
use was assessed by twice interviewing one-tenth of the ran-
domly selected subjects using the same questionnaire. The
overall agreement in reported ginseng use between the two
interviews was 0.85, and the k value was 0.71 (p<0.01)
(Table 4). These results strongly support the hypothesis that
ginseng has cancer preventive effects, as suggested by the
previous animal experiments (8-17).
1,987 pairs case-control study
In this study, as with the previous study, ginseng users had
a lower risk (OR; 0.50) for cancer compared with non-users.
With respect to the type of ginseng, the ORs for cancer were
0.37 for fresh ginseng extract users, 0.57 for white ginseng
extract users, 0.30 for white ginseng extract users, 0.30 for
white ginseng powder users, and 0.20 for red ginseng users
(Table 5). Those who took fresh ginseng slices, fresh ginseng
juice, and white ginseng tea, however, showed no decrease
in the risk. Overall, the risk decreased as the frequency and
duration of ginseng intake increased, showing a dose-response
relationship (Table 6). With respect to the site of cancer, the
odds ratios were 0.47 for cancer of lip, oral cavity, and phar-
ynx; 0.20 for esophageal cancer; 0.36 for stomach cancer;
0.42 for colorectal cancer; 0.48 for liver cancer; 0.22 for
pancreatic cancer; 0.18 for laryngeal cancer; 0.55 for lung
cancer; 0.15 for ovarian cancer; and 0.48 for other cancers
(Table 7). With cancers of the female breast, uterine cervix,
urinary bladder, and thyroid gland, however, there was no
benifit with ginseng intake. In cancers of lung, lip, oral cav-
ity, pharynx, and liver, smokers who took ginseng showed
decreased OR compared with smokers with no ginseng
intake. These findings supported the view that the use of
ginseng decreased the risk for most cancer compared to the
non-user. Smokers without ginseng intake showed signifi-
cantly increased risks for cancers of lung, lip, oral cavity,
pharynx, and liver. However, the ORs for smokers who had
consumed ginseng decreased, showing 1.99 for lung, 2.36
for lip, oral cavity, and pharynx cancers, and 2.09 for liver
cancer compared with nonsmokers who had consumed gin-




Controls Cases  Odds ratios (95% CI) Cases Controls Odds ratio (95% CI)
No intake 117 56 1.00 226 175 1.00
1-3 times/yr 132 108 0.58 (0.38-0.90) 111 106 0.81 (0.57-1.15)
4-11 times/yr 104 115 0.43 (0.28-0.67) 75 103 0.56 (0.39-0.82)
Once/month or more 83 157 0.25 (0.16 - 0.39) 57 85 0.52 (0.35-0.78)
Total 436 436 469 469
Linear trend test (1 d.f.) 45.59 (p<0.0001) 3.98 (p<0.05)
×2 homogeneityt test (3 d.f.) 47.28 (p<0.0001) 16.53 (p<0.001)
Table 3. Odds ratios of cancer in ginseng intake frequency and 95 % confidence intervals in 905 pairs case-control study 
Second interview
First interview
None Fresh ginseng White ginseng Total
None 0.57 (104) 0.05 ( 9) 0.01 (2) 0.63 (115)
Fresh ginseng 0.05 (8) 0.21 (39) 0.01 (1) 0.27 (48)
White ginseng  0.02 (4 ) 0.01 (1) 0.07 (12) 0.10 (17)
Total 0.64 (116) 0.27 (49) 0.07 (15) 1.00 (180)
Table 4. Subjects response to ginseng intake questions at two
different interviews
Overall proportion of observed agreement
P0=0.57+0.21+0.07=0.85
Overall proportion of chance-expected agreement
pe=0.64×0.63+0.27×0.27+0.09×0.11=0.49
Kappa value
A       0.85-0.49      0.71 (p<0.01) k          1-0.49
Type of ginseng Cancer
patients
Controls Odds ratio 95% CI
No intake of ginseng 921 605 1.00 Reference
Intake of ginseng 1,066 (62%) 1,382 (75%) 0.50 0.44-0.58
Fresh ginseng
Slice 210 172 0.79 0.63-1.01
Juice 69 63 0.71 0.49-1.03
Extract 146 255 0.37 0.29-0.46
White ginseng
Powder 60 129 0.30 0.22-0.41
Extract 373 442 0.57 0.48-0.68
Tea 43 41 0.69 0.45-1.07
Red ginseng
Extract 6 17 0.20 0.08-0.50
Combination 22 58 0.16 0.10-0.25
Table 5. Odds ratios and 95% confidence intervals for cancers
by ginseng intake in 1,987 pairs
Adjusted for age, sex, marital status, educations, smoking, and alcohol
consumption.
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was no association with ginseng intake (Table 8).
Cohort study on population
The total number of subjects interviewed was 4,675. Out
of them, 41 prevalent cancer cases were excluded, and the
remaining 4,634 eligible subjects (2,362 men and 2,272
women) were selected for analysis. From 4,634 people eligi-
ble for analysis, 47 unknown diseases were excluded, and
54.7% of 137 cancer cases had history of ginseng intake in
comparison with 71.2% of 4,450 non-cases, showing simi-
lar proportion to those of the control groups in the previous
case-control studies [74.5% (Table 2) and 69.6% (Table 5)
(18, 19)]. The present study showed a significant reduction
of relative risk (RR) (0.40) by the intake of ginseng (Table
9), as shown in the previous case-control studies. On the
type of ginseng, the RRs for cancer in fresh ginseng extract
consumers and consumers with multiple combinations were
significantly reduced (Table 9). The RRs for other types of
ginseng including white ginseng tea showed a decreasing
trend, but was not statistically significant. Among 24 red
ginseng consumers, there were no deaths from cancer. The
results showed no relationship between fresh ginseng con-
sumers and cancer, which was consistent with the experi-
mental study (12-17) and case-control studies (18, 19).
There was a decreased risk with increased frequency of gin-
seng consumed, showing a significant dose-response rela-
tionship (Table 10).
During the study period, 137 cases including 42 stomach,
24 lung, 14 liver and 57 at other sites were diagnosed as
cancers. The RRs in ginseng consumers were 0.33 (95%
CI: 0.18-0.57) for gastric cancer and 0.30 (95% CI: 0.14-
0.65) for lung cancer, showing a statistical significance (Table
11). Among ginseng preparations, only fresh ginseng extract
consumers, a decreased risk for gastric cancer (RR=0.33, 95%
CI: 0.12-0.88 was observed), while other types of ginseng
Ginseng intake 
Males Females
Controls Odds ratio Case 95% CI Cases Controls Odds ratio 95%
Frequency of ginseng intake
None 409 234 1.00 Reference 512 371 1.00 Reference 
1-3 times/yr 246 231 0.62 0.49-0.79 171 209 0.60 0.47-0.76
4-11 times/yr 197 223 0.48 0.37-0.62 127 171 0.54 0.42-0.71
1 time/month or more 220 384 0.31 0.25-0.39 105 164 0.47 0.39-0.62
Total lifetime consumption of ginseng
None 409 452 1.00 Reference 512 371 1.00 Reference
1-50 452 501 0.51 0.42-0.63 322 402 0.58 0.48-0.71
51-100 75 100 0.41 0.29-0.58 28 39 0.56 0.34-0.93
101-300 80 131 0.32 0.23-0.44 29 54 0.39 0.25-0.61
301-500 20 29 0.33 0.18-0.62 8 21 0.29 0.14-0.63
500- 36 77 0.25 0.16-0.38 16 28 0.42 0.23-0.79
Table 6. Distribution of ginseng intake frequency in cases and controls by sex: Odds ratios for cancer and 95 percent confidence
interval in case-control study with 1,987 pairs
Site of cancer
Cases Controls
Never taken/ever taken Never taken/ever taken
Odd ratios 95% CI
Lip, oral cavity, and pharynx 67/92 40/119 0.47 0.29±0.76
Esophagus 40/47 14/73 0.20 0.09±0.38
Stomach 142/158 76/224 0.36 0.09±0.52
Colon and rectum 55/63 32/86 0.42 0.24±0.74
Liver 108/156 67/197 0.48 0.33±0.70
Pancreas 12/11 5/18 0.22 0.05±0.95
Larynx 21/19 8/32 0.18 0.06±0.54
Lung 120/156 81/195 0.55 0.38±0.79
Female breast 82/92 70/109 0.63 0.40±1.05
Cervix uteri 156/146 312/170 0.72 0.52±1.01
Ovary 17/5 8/14 0.15 0.04±0.60
Urinary bladder 23/40 16/47 0.64 0.28±1.47
Thyroid gland 16/24 14/26 0.96 0.38±2.44
Other 53/61 35/79 0.48 0.27±0.85
Table 7. Odds ratios for various cancers according to ginseng intake in case-control study with 1,987 pairs
Adjusted for age, sex, marital status, education, smoking, and alcohol consumption.S24 T.-K. Yun, S.-Y. Choi, H.Y. Yun
showed a decreasing trend. 
DISCUSSION
In China, red ginseng was found to inhibit development
of diethylnitrosamine-induced liver cancer in rats (25) and
skin cancer in mice (26). In Russia, tissue-culture biomass
tincture obtained from cultured Panax ginseng cells was
shown to have a strong inhibitory effect on rat mammary
adenocarcinoma induced by methyl-N-nitrosourea (27) as
well as development of experimental uterine cervix and vagi-
nal tumors (28). The result that 12-o-tetradecanoylphorbol-
13-acetate (TPA)-induced production of tumor necrosis fac-
tor in mouse skin was inhibited by methanol extract of
heat-processed neoginseng pretreatment was obtained in
Korea (29). Recently, Japanese workers observed that, dietary
administration of red ginseng powder during the initiation
stage of carcinogenesis suppressed preneoplastic lesions in
the colon of rats induced by 1,2-dimethylhydrazine (30). In
MCF-7 breast cancer cells, the ability of American ginseng
to induce the oestrogen-regulated gene pS2 and to regulate
the cell-cycle were assessed in the U.S.A. Both American
ginseng and oestradiol equally induced pS2 RNA expression,
but only the ginseng caused a dose-dependent decrease in
cell proliferation (31). 
In case-control studies with 905 pairs and 1,987 pairs,
there was noticeable decrease in risk by intake of ginseng
extract compared to intake of fresh ginseng and there was a
dose-response relationship depending on frequency of gin-
seng intake. The ORs of ginseng consumers decreased in all
kinds of cancers. These results strongly support the hypoth-
esis that ginseng has cancer preventive effects, as suggested
by the earlier animal experiments. Lancet stated in an edito-
rial that our study was one example of needed research into
non-organ specific strategies for cancer control (32). Further-
more, the results of the cohort study also suggest that Panax
ginseng C.A. Meyer has non-organ specific preventive effect
against cancer, providing support for the previous case-con-
trol studies.
By comparing experimental results of types and ages of
ginseng including two case-control and one cohort studies,
the result with less than 5 yr-fresh ginseng was negative in
both experimental and epidemiological studies but positive
Cancers Ginseng intake
Nonsmokers Smokers
95% CI Odds ratio Odds ratio 95% CI
Lung Ever taken 1.00 (27)* Reference 1.99 (81) 1.25-3.19
Never taken 2.11 (40) 1.08-4.15 4.13 (128) 1.90-9.03
Lip, oral cavity, and pharynx  Ever taken 1.00 Reference  2.36 (43) 1.23-4.51
Never taken 2.13 (24) 0.95-4.79 4.41 (69) 1.29-15.04
Esophagus Ever taken 1.00 (5) Reference 0.13 (35) 0.06-0.31
Never taken 0.51 (5) 0.10-2.69 0.38 (42) 0.09-1.62
Stomach Ever taken 1.00 Reference 2.90 (62) 1.79-4.70
Never taken 2.73 (80) 1.61-4.64 1.90 (101) 0.84-4.28
Colorectum Ever taken 1.00 (31) Reference 3.25 (20) 1.25-8.44
Never taken 2.11 (35) 1.03-4.34 2.45 (31) 0.60-10.13 
Liver Ever taken 1.00 (31) Reference 2.09 (81) 1.33-3.29
Never taken 1.68 (27) 0.79-3.57 2.50 (125) 1.06-5.92
Table 8. Odds ratios for cancers according to ginseng intake and smoking in case-control study with 1,987 pairs
Adjusted for age, sex, education, and alcohol consumption. *: Odds ratio (No. of patients)







No intake 1,283 62 1.00 -
Ginseng intake 3,167 75 0.40* 0.28-0.56
Slices & juice 236 8 0.67 0.33-1.32
Extract 296 3 0.31* 0.13-0.74 
White ginseng
Powder 147 5 0.49 0.19-1.23
Extract 68 1 0.50 0.12-2.07
Tea 442 18 0.65 0.37-1.12
Red ginseng
Extract 24 -- -
Boiled chicken with
young ginseng root 381 12 0.71 0.38-1.21
Multiple combination 1,573 28 0.34* 0.20-0.53
Table 9. Relative risks for cancer by ginseng intake in cohort
study
Relative risks, adjusted for age, sex, education, smoking and  alcohol
consumption; *: p<0.05
Frequency of






No intake 1,283 62 1.00 -
1-3 times/yr 1,439 39 0.46 0.30-0.69
4-11 times/yr 924 21 0.35 0.21-0.58
Once/month or more 804 15 0.34 0.20-0.59
Table 10. Relative risks for cancer according to frequency of
ginseng intake in cohort study
Adjusted for age, sex, education, smoking and alcohol consumption.Epidemiological Study on Cancer Prevention by Ginseng: Are All Kinds of Cancers Preventable by Ginseng? S25
in fresh ginseng extract (Table 12). On the other hand, there
was no cancer death among 24 red ginseng consumers, and
red ginseng products showed prominent preventive effect in
the 9 week anticarcinogenicity test model (Yun’ s model) and
both case-control and cohort studies.
In order to compare the dose-response relationship between
ginseng consumption and trend test of the above described
results showed a significant decrease in proportion of cancer
cases with increasing frequency of intake for both males and
females (Table 13).
Experimental studies on ginseng has been widely carried
out in many countries including Korea, China, Japan and
Russia. The results indicated ginseng as an agent for anti-
carcinogenicity as well as antipromoter. However, epidemi-
ological studies were published only by our groups, includ-
ing two case-control and one cohort studies.
In these three epidemiological studies, we demonstrated
that Panax ginseng C.A. Meyer decreased the risks for most
types of human cancers with dose response relationship, that
is, non-organ specific cancer preventive effects (32-35). The
need for clinical studies of ginseng has been strongly recom-
mended (36-40). Clinical trials of Panax ginseng extracts and
its active compounds are now warranted to be tested for a






Stomach (42) Lung (24) Liver (14)
No. RR 95%  CI No. RR 95%  CI No. RR 95%  CI
No intake 1,283 23 1.00 - 14 1.00 - 4 1.00 -
Ginseng intake 3,167 19 0.33* 0.18-0.57 10 0.30* 0.14-0.65 10 0.86 0.25-2.94 
Slices & juice 236 2 0.57 0.17-1.94 1 0.67 0.15-3.43 2 1.97 0.34-2.95
Extract 296 1 0.33* 0.12-0.88 1 0.28 0.04-2.17 --
White ginseng 
Powder 147 1 0.24 0.03-1.84 -- - - - -
Extract 68 2 1.34 0.30-5.97 -- - - - -
Tea 442 6 0.64 0.26-1.61 4 0.80 0.26-2.44 2 1.72 0.15-4.87
Red ginseng
Extract
Boiled chicken with 381 5 0.43 0.12-1.43 1 0.35 0.08-1.95 1 0.85 0.15-4.87
young ginseng root
Table 11. Adjusted relative risks for selected cancers by ginseng intake in cohort study 
RR: Relative risks, adjusted for age, sex, education, smoking and alcohol consumption; *: p<0.05; CI: Confidence interval; Value in parentheses indi-
cate number of cancer cases.
Kind of ginseng
Anticarcinogenicity confirmed by
Yun’ s test model
Case-control studies Cohort study based on population
1,987 pairs Relative risks 905 pairs Relative risks 4,634 persons/5 yr Odds ratios
Ginseng intake 0.56* 0.50* 0.40*
Fresh ginseng
Fresh slices 1.5, 3, 4 and 5 yr-old 0.74 0.79 0.67 
6 yr-old only *
Extract 1.5, 3, 4 and 5 yr-old 
6 yr-old only * 0.14* 0.37* 0.31* 
White ginseng
Powder 1.5, 3 and 4 yr-old 
5 and 6 yr-old* 0.44* 0.30* 0.49 
Extract 1.5, 3 and 4 yr-old 
5 and 6 yr-old* 0.64* 0.57* 0.50 
Red ginseng
Extract 1.5 and 3 yr-old 
4,5 and 6 yr-old*  0.45 0.20* 24 participants 
Powder 1.5 and 3 yr-old  = No cancer death =
4,5 and 6 yr-old*
Combination -  0.27* 0.16* 0.34* 
Table 12. Comparison of relative risks for cancer by type of ginseng intake by medium-term experiment, case-control studies and
cohort study
Adjusted for age, sex, education, smoking, alcohol consumption; *: Statistically significant.S26 T.-K. Yun, S.-Y. Choi, H.Y. Yun
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